Beverly, MA (GLOBE NEWSWIRE) - LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that Dr. Jack Regan, LexaGene’s CEO and Founder, was invited by the Food Safety and Inspection Service (FSIS), an agency of the United States Department of Agriculture (USDA), to present a seminar on the benefits of using LexaGene’s LX technology to help detect contaminated food items and prevent recalls.
Invited guests of this seminar include individuals representing multiple federal agencies such as the Food and Drug Administration (FDA), the Animal and Plant Health Inspection Service (APHIS), the Centers for Disease Control and Prevention (CDC), the Environmental Protection Agency (EPA), the National Institute of Food and Agriculture (NIFA), the Food & Nutrition Service (FNS), the Agricultural Research Service (ARS), and the Agricultural Marketing Service (AMS).
Dr. Regan’s presentation on using rapid genetic analysis for automated pathogen testing in the food industry will be given as part of the FSIS Science and Technology Seminar Series on June 19, 2019, from 1-2 pm EDT at Patriots Plaza III in Washington, DC. The FSIS Seminar Series fosters information exchange between FSIS personnel and professionals in public health, food science and technology, microbiology, risk assessment, infectious disease, veterinary medicine and other related sciences.
Dr. Jack Regan, LexaGene’s CEO and Founder, states, “I’m honored to be selected by the USDA to present on this topic. I look forward to sharing my knowledge and passion on the advantages of using LexaGene’s technology to dramatically improve food safety.”
To be added to the LexaGene email distribution list, please subscribe on the Company website here.
About LexaGene Holdings Inc.
LexaGene is a biotechnology company commercializing the very first easy-to-use, fully automated, genetic analyzer that is open-access. The open-access feature empowers end-users to target any genetic sequence of interest, whether of pathogen or human origin. To take advantage of the open-access feature, end-users simply need to load their own real-time PCR assays onto the instrument to customize their tests or run validated assays the company is developing. LexaGene’s analyzers offer excellent sensitivity, specificity, and breadth of pathogen detection while returning results in about 1 hour. The company expects to sell its technology in the food safety and veterinary diagnostics markets, as well as to markets that need easy-to-use customized testing such as biotechnology and pharmaceutical companies, academia, and institutions performing water quality monitoring, aquaculture pathogen surveillance, and others.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
© 2019 GlobeNewswire, Inc. All Rights Reserved.
SOURCE: LexaGene Holdings Inc